These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29117155)

  • 1. Therapeutics: Spoilt for choice.
    Eisenstein M
    Nature; 2017 Nov; 551(7679):S36-S38. PubMed ID: 29117155
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.
    Hsu FS; Su CH; Huang KH
    J Immunol Res; 2017; 2017():6940546. PubMed ID: 29376081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
    Gill DM; Sonpavde G; Pal SK; Agarwal N
    Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
    [No Abstract]   [Full Text] [Related]  

  • 5. Nivolumab Gets FDA Nod for Bladder Cancer.
    Cancer Discov; 2017 Apr; 7(4):OF7. PubMed ID: 28183696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
    Necchi A; Raggi D; Giannatempo P; Sonpavde G; Galsky MD; Bellmunt J; Mariani L; Miceli R
    Clin Genitourin Cancer; 2017 Oct; 15(5):509-512.e9. PubMed ID: 28478885
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune checkpoint blockade therapy for bladder cancer treatment.
    Kim J
    Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S98-S105. PubMed ID: 27326412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
    Galsky MD
    Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
    [No Abstract]   [Full Text] [Related]  

  • 9. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 10. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Dangling" Accelerated Approvals in Oncology.
    Beaver JA; Pazdur R
    N Engl J Med; 2021 May; 384(18):e68. PubMed ID: 33882220
    [No Abstract]   [Full Text] [Related]  

  • 12. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer.
    Saad FT; Hincal E; Kaymakamzade B
    Comput Math Methods Med; 2017; 2017():3573082. PubMed ID: 29312460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Immunotargets in Bladder Cancer.
    Massari F; Ciccarese C; Vau N; Santoni M; Montironi R; Cheng L; Marques RC; Scarpelli M; Fonseca J; Matrana MR; Holger M; Cascinu S; Tortora G; Lopez-Beltran A
    Curr Drug Targets; 2016; 17(7):757-70. PubMed ID: 26844572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
    Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
    Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
    [No Abstract]   [Full Text] [Related]  

  • 17. Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
    Bourlon MT; Velázquez HE; Luna-Santiago R; Vázquez-Manjarrez S; Bourlon C
    Oncology (Williston Park); 2018 Feb; 32(2):64-8. PubMed ID: 29492946
    [No Abstract]   [Full Text] [Related]  

  • 18. A Reality Check for Checkpoint Inhibitors.
    Reinke T
    Manag Care; 2018 May; 27(5):12-13. PubMed ID: 29763400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approvals in 2016: the march of the checkpoint inhibitors.
    Blumenthal GM; Pazdur R
    Nat Rev Clin Oncol; 2017 Feb; 14(3):131-132. PubMed ID: 28218255
    [No Abstract]   [Full Text] [Related]  

  • 20. Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
    Parikh RB; Adamson BJS; Khozin S; Galsky MD; Baxi SS; Cohen A; Mamtani R
    JAMA; 2019 Sep; 322(12):1209-1211. PubMed ID: 31550019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.